TP53 and breast cancer: Large-scale meta-analyses across heterogeneous breast cancer datasets analyzed on different expression microarray platforms of multigene signatures like the 70-gene Mammaprint signature (NKI-70) [6], Celera 14-gene metastasis score (MS-14) [16], 76-gene Veridex signature (EMC-76) [17], core serum response (CSR/wound) signature [18], Oncotype/Genomic Health recurrence score (ONCO-RS) [19], p53 [20], and genomic grade index (GGI) [21] have shown that their prognostic values are comparable when evaluated against HRpos breast cancers (with or without adjuvant treatment).